Zai Lab Ltd (ZLAB NASDAQ) stock market data APIs
$20.4951
0.13(0.6%)
as of May 15, 2026
Try our APIs with
free plan!
Zai Lab Ltd Financial Data Overview
Price chart is built with
Anychart
Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy; NUZYRA for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections; Optune for glioblastoma multiforme; Qinlock for gastrointestinal stromal tumors; Xacduro for treating hospital-acquired and ventilator-associated bacterial pneumonia caused by a cinetobacter baumannii-calcoaceticus complex; and Augtyro for the treatment of ROS proto-oncogene 1 and non-small cell lung cancer. The company has a strategic collaboration with Tesaro, Inc., NovoCure Ltd., Deciphera Pharmaceuticals, LLC, Paratek Bermuda Ltd., argent BV, Turning Point Therapeutics, Inc., Entasis Therapeutics Holdings Inc., Karuna Therapeutics, Inc., Pfizer Inc., Amgen Inc., and with Boehringer Ingelheim GmbH. The company was incorporated in 2013 and is based in Pudong, China.
Prev. Close
20.4951
Open
20.514
High
21.2285
Low
20.3385
52 wk Range
15.96-44.34
Market Cap
2 313 M
Shares Outstanding
112 M
Revenue
460 M
EPS
-0.46
Beta
0.845
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Zai Lab Ltd (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Zai Lab Ltd data using free add-ons & libraries
Get Zai Lab Ltd Fundamental Data
Zai Lab Ltd Fundamental data includes:
- Net Revenue: 460 M
- EBITDA: -214 424 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-05-12
- EPS/Forecast: -0.2909
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Zai Lab Ltd News
New
Asian Equities Traded in the US as American Depositary Receipts Fall Sharply in Friday Trading
Asian equities traded in the US as American depositary receipts were falling sharply Friday morning, PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscri...
Asian Equities Traded in the US as American Depositary Receipts Open Week Lower in Monday Trading
Asian equities traded in the US as American depositary receipts opened the week tracking modestly lo PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscri...
Zai Lab Limited (NASDAQ:ZLAB) Analysts Are Cutting Their Estimates: Here's What You Need To Know
It's been a mediocre week for Zai Lab Limited (NASDAQ:ZLAB) shareholders, with the stock dropping 12% to US$18.60 in the week since its latest quarterly results. The results weren't stellar - revenue ...
Zai Lab wins FDA fast track status for cancer drug zocilurtatug pelitecan
Zai Lab (ZLAB [https://seekingalpha.com/symbol/ZLAB]) said the U.S. FDA granted fast track designation to its experimental cancer drug zocilurtatug pelitecan for treating extrapulmonary neuroendocrine...
Get Zai Lab Ltd fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
